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  47 
Abstract  48 
 49 
It is now well established that cancer cells co-exist within a complex environment with 50 
stromal cells and depend for their growth and dissemination upon tight and plastic interactions 51 
with components of the tumor microenvironment (TME). Cancer cells incite the formation of 52 
new blood and lymph vessels from preexisting vessels, to cope with their high 53 
nutrient/oxygen demand and favor tumor outgrowth. Research over the past decades, has 54 
highlighted the crucial role played by tumor-associated blood and lymph vasculature in 55 
supporting immunoevasion and in subverting T cell-mediated immunosurveillance, which are 56 
main hallmarks of cancers. The structurally and functionally aberrant tumor vasculature 57 
contributes to the protumorigenic and immunosuppressive TME, by maintaining a cancer 58 
cell’s permissive environment characterized by hypoxia, acidosis and high interstitial 59 
pressure, while simultaneously generating a physical barrier to T cells infiltration. Recent 60 
research moreover, has shown that blood endothelial cells forming the tumor vessels can 61 
actively suppress the recruitment, adhesion and activity of T cells. Likewise, during 62 
tumorigenesis the lymphatic vasculature undergo dramatic remodeling that facilitates 63 
metastatic spreading of cancer cells and immunosuppression.  Beyond carcinogenesis, the 64 
erratic tumor vasculature has been recently implicated in mechanisms of therapy resistance, 65 
including those limiting the efficacy of clinically approved immunotherapies, such as immune 66 
checkpoint blockers and adoptive T cell transfer.   67 
In this review, we discuss emerging evidence highlighting the major role played by tumor-68 
associated blood and lymph vasculature in thwarting immunosurveillance mechanisms and 69 
antitumor immunity. Moreover, we also discuss novel therapeutic approaches targeting the 70 





• Cancer cell and stromal cell interface enforces a tumor microenvironment (TME) that 76 
is permissive for tumor growth. 77 
• The dynamic properties of the TME regulate how malignant cells respond to therapy.  78 
• Cancer cell-derived proangiogenic factors triggers unproductive angiogenesis and 79 
lymphangiogenesis that facilitate tumor growth and metastasis.  80 
• The structurally and functionally abnormal tumor blood and lymph vasculature favor 81 
escape of malignant cells from antitumor immunity and fosters the 82 
immunosuppressive TME. 83 
• Endothelial cells of the tumor vasculature actively suppress antitumor immunity by 84 
regulating recruitment, adhesion and function of immune cells and by inducing killing 85 
of effector T cells. 86 
• A complex bidirectional interface between tumor vasculature and the immune cells 87 
regulates therapy responses. 88 
• Targeting the tumor vasculature with antiangiogenic agents allows a transient 89 
improvement of the vessels that improves tumor oxygenation and enhances drug 90 
delivery, immune cells infiltration and immunotherapy efficacy.  91 
 92 
Open questions 93 
• What are the molecular mechanisms regulating the intense crosstalk between 94 
endothelial cells and immune cells within the tumor microenvironment?  95 
• What is the role of other stromal cells (e.g. cancer derived fibroblasts) in tumor 96 
angiogenesis?  97 
• Which vasculature-targeting approaches can ‘heat up’ the tumor microenvironment 98 
and favor infiltration of T cells?  99 
• Which tumor vasculature-targeting regimens create the best window of opportunity 100 
required for a durable effect on immunostimulating tumor microenvironment? 101 
• Which pathway and endothelial cell-specific molecular target should we target to 102 
improve therapy responses? 103 
• How should the lymphatic system be targeted considering that it serves peripheral 104 
tolerance but also facilitates adaptive immune response by draining tumor-associated 105 
antigen(-presenting DC)?  106 
• What are the best treatment scheduling options for antiangiogenic therapies when 107 
combined with immunotherapy modalities? 108 
• Do tumor vessel normalizing strategies offer a best treatment strategy to improve T 109 
cell function and immunotherapy? 110 
• Does the concept of vessel normalization extend to the lymphatic vasculature and 111 
what are the underlying mechanisms? 112 
• Do vessel normalizing strategy in combination with immunogenic cell death-based 113 
approaches synergize? 114 
• Which biomarkers will allow monitoring the effects of vessel normalizing drugs on 115 
patient’s immunological responses to therapy?  116 
 117 
 118 
  119 
The crosstalk between cancer cells and stromal cells shapes the tumor 120 
microenvironment  121 
 122 
In recent years, tumors have been recognized as complex dysorganized and chaotic organs, 123 
where cancer cells co-exist and co-evolve with their stroma. This view is a major shift from 124 
the previously accepted ‘cancer cell-centered’ perception of cancer evolution, which mainly 125 
focused on understanding oncogenic drivers and cell-autonomous features of cancer. It is now 126 
increasingly accepted that the interface between malignant and non-transformed cells defining 127 
the tumor microenvironment (TME), represents a highly plastic tumor ecosystem that 128 
supports tumor growth and dissemination through the various stages of carcinogenesis. Apart 129 
from cancer cells, the TME of a solid tumor, contains a complex interstitial extracellular 130 
matrix and various stromal cells that are recruited from the surrounding tissues or from the 131 
bone marrow1 and include fibroblasts, cells of the immune systems, pericytes and endothelial 132 
cells of the blood and lymphatic vasculature.  133 
Within the TME cancer cells thrive and maintain a dynamic communication with all TME 134 
components through the release of soluble factors (e.g. cytokines, chemokines, growth and 135 
inflammatory factors, lipid mediators, matrix remodelling enzymes) or through cancer cell-136 
stromal cells contacts, which ultimately drive a chronic inflammatory, immunosuppressive 137 
and pro-angiogenic niche that promotes dissemination of cancer cells and thwarts the effects 138 
of various therapeutic interventions, including immunotherapy. Moreover, this intersection is 139 
bi-directional, since each stromal component of the TME may establish a proficient interface 140 
with cancer cells, which facilitates cancer progression, at virtually any stage of tumorigenesis. 141 
For example, a large body of experimental evidence supports the concept that the immune 142 
system is able to eradicate emerging tumors, through the process of cancer 143 
immunosurveillance, before cancer cells evolve the ability to erode detection and eradication 144 
by immune cells2, 3. Distinguishing mechanisms enabling an immunoevasive cancer cell 145 
phenotype include, a reduced immunogenicity due to loss in expression of tumor-associated 146 
antigens (TAAs) or major histocompatibility complex (MHC) class I molecules, acquired 147 
DNA copy number alterations and oncogenic signaling, upregulation of cellular immune 148 
checkpoints like Programmed death ligand (PD-L)1, indoleamine 2,3-dioxygenase (IDO), 149 
tryptophan 2,3-dioxygenase (TDO), and altered metabolism resulting in a low pH and 150 
secretion of various metabolites4. Moreover, through increased production of 151 
immunosuppressive and tumor-promoting cytokines, cancer cells modulate the polarization, 152 
activity and expansion of various immune cell subpopulations and interface with endothelial 153 
cells (ECs), causing alterations in their structural integrity and functional properties, thus 154 
diminishing antitumor immune responses.  155 
In fact, cancer immunosurveillance which is driven largely by activated effector T cells, is 156 
impaired at different levels by several obstacles imposed by the increasingly hostile TME. To 157 
exert their function, T cells need to be properly activated by antigen-presenting dendritic cells 158 
(DCs), usually by encountering DCs in peripheral lymph nodes (LNs), egress the LNs and 159 
home to the tumor and finally extravasate from blood vessels and infiltrate the tumors. 160 
Thereafter, activated CD8+ T cells can recognize TAA presented through a MHC class I 161 
molecule on cancer cells and induce their killing via the perforin-granzyme and/or Fas ligand 162 
(FasL)/tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) systems, 163 
although this depends on the degree of functional inhibition by the TME and the presence of 164 
immunosuppressive regulatory T cells (Tregs), myeloid derived suppressor cells (MDSCs), and 165 
tumor-associated macrophages (TAMs).  In this scenario, the blood and lymph vasculature 166 
have important roles as physical and functional barriers for tumor infiltrating immune cells 167 
and TAA/TAA-presenting DC drainage to the LNs, respectively.  168 
Finally, such an intense crosstalk between cancer cell and stromal cells, not only promotes 169 
tumor growth and dissemination but also gravely affects the efficacy of multimodal anticancer 170 
treatment. This is particularly true for the currently, clinically used cancer immunotherapies, 171 
such as those employing immune checkpoint inhibitors (ICIs) or adoptive T cell transfer 172 
(ACT), that primarily aim to reinvigorate antitumor T cell activity. 173 
Here we aim to discuss the current view on the cancer cell-induced alterations in the blood 174 
and lymphatic vasculature as well as (sentinel) lymph nodes that profoundly impede 175 
antitumor immunity. We also summarize the advances and therapeutic combinations targeting 176 
the tumor vasculature that may overcome immunotherapy resistance.   177 
 178 
 179 
Tumor-associated blood vasculature favors an immunoresistant tumor 180 
microenvironment 181 
 182 
Solid tumors that have grown beyond few cubic millimeters need to induce tumor 183 
angiogenesis, to receive nutrients (e.g. oxygen and glucose) required for their high energy 184 
demand and growth. Tumor angiogenesis, entails the development of new blood vessels from 185 
established vascular beds and as such is different from vasculogenesis (de novo formation of 186 
vessels from bone marrow-derived endothelial precursor cells) or vasculogenic mimicry (the 187 
ability of tumor (stem) cells to form vessel-like networks)5. The formation of a novel vascular 188 
sprout is a dynamic and tightly orchestrated process that involves the coordinated action of 189 
the highly invasive and motile tip cells at the leading edge (migrating towards pro-angiogenic 190 
cues and guided by key pro-angiogenic Vascular Endothelial Growth Factor (VEGF)-A - 191 
Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) axis), and the underlying 192 
proliferating stalk cells, elongating the sprout and generating the lumen. Such fully formed 193 
vessel recruits pericytes and vascular smooth muscle cells thereby promoting stability, 194 
integrity and blood perfusion (extensively review in6, 7). 195 
Pathological angiogenesis is mainly driven by an imbalance between pro- and anti-angiogenic 196 
signaling in the TME. Key pro-angiogenic factors include, but are not limited to, VEGF-A, 197 
basic fibroblast growth factor (bFGF) and interleukin (IL)-8. These cytokines become 198 
ubiquitously abundant in the TME and overwhelm angiostatic signals, such as angiostatin and 199 
endostatin, thereby inducing a pro-angiogenic switch8. In fact, not only cancer cells secrete 200 
high amount of VEGF, and can contribute to VEGF-independent angiogenesis (by liberating 201 
various pro-angiogenic molecules such as placental growth factor (PlGF), VEGF-C, VEGF-D, 202 
platelet-derived growth factor (PDGF)-C), but they can also respond in an autocrine or 203 
paracrine manner to prosurvival and prometastatic VEGF-signaling5.  Although tumor 204 
angiogenesis is meant to support blood supply to the tumor, the resulting vessel network is 205 
leaky, chaotically organized, immature, thin-walled and ill-perfused (Fig.1). This 206 
unproductive, highly aberrant angiogenesis contributes to maintain the protumorigenic and 207 
immunosuppressive TME and profoundly influences how cancer cells escape the anticancer 208 
immunosurveillance, metastasize and, respond to immunotherapy. 209 
A chaotic vascular network, that gives rise to blunt-ended vessels and inconsistent blood 210 
flow9, is associated with structurally immature vessels that are unstable, leaky and tortuous. 211 
Ill-covered perfusion results in diffusion-limited nutrient delivery (cells are too far from 212 
functional vessel). Moreover, due to the high interstitial fluid pressure (IFP) in the tumor (a 213 
result of vessel leakiness) these vessels are prone to collapse and diminish the perfused tumor 214 
area6 (Fig.1). 215 
This generates a hypoxic (i.e. less oxygenated) and acidic (due to increased anaerobic 216 
glycolysis of cancer cells) TME that facilitates the selection of cancer cells with genetic (i.e. 217 
enumeration of mutations favoring malignancy) and epigenetic alterations that enhance their 218 
aggressiveness. Importantly, hypoxia and acidosis (reviewed in10) facilitate 219 
attraction/development of immunosuppressive immune cells, reduce the cytotoxic activity of 220 
tumor infiltrating effector T cells,  hamper delivery of chemotherapeutics and 221 
immunotherapeutic entities, as well as cancer cell killing in response to radio/chemotherapy 222 
and immunotherapy (as discussed later). 223 
 224 
Here, we discuss some of the major mechanisms imposed by the erratic tumor vasculature to 225 
reverse or prevent antitumor immune responses (Fig. 2). 226 
 227 
Accessibility of immune cells to the tumor bed. A hypoxic TME is associated with high 228 
VEGF-A, IL-10 and prostaglandin E2 (PGE2) levels. These factors collectively induce FasL 229 
expression on tumor ECs, which upon binding to Fas expressed on T cells, triggers their 230 
killing by apoptosis. Due to a differential expression of c-FLIP (a known suppressor of TNF, 231 
FasL and TRAIL induced apoptosis11), CD8+ T cells are more adversely affected by these 232 
events than Tregs 12. Moreover, tumor-associated ECs can preferentially promote the 233 
recruitment of Tregs by the upregulation of the multifunctional endothelial receptor CLEVER-234 
1/stabilin-1, thus suggesting that tumor endothelium can support both the recruitment and the 235 
survival of immunosuppressive T cells13. In addition, VEGF-A mediates a clustering defect of 236 
the adhesion molecules like intercellular adhesion molecule (ICAM)-1 and vascular cell 237 
adhesion protein (VCAM)-1, which hampers immune cell extravasation14. Thus, aside from 238 
stimulating angiogenesis, VEGF-A also contributes to the impediment of an efficient EC-239 
lymphocyte interaction. Furthermore, the endothelin B receptor (ET-BR; receptor of the 240 
hypoxia-inducible factor (HIF)-1-regulated endothelin-1)) on tumor ECs is implicated in 241 
counteracting T cell adhesion as neutralization of ET-BR increases tumor-infiltrated 242 
lymphocytes (TILs) and improves responsiveness to immunotherapy 15.  Although these 243 
adhesion molecules can bind multiple leukocyte subtypes, it is still unclear which 244 
compensatory signals maintain the intratumoral presence of monocytes and neutrophils. 245 
 246 
Maturation and polarization of immune cells. Hypoxia-induced signaling mediates the 247 
presence of certain immunosuppressive immune cell types including immature DCs, tumor-248 
associated macrophages and neutrophils (TANs), as well as, MDSCs. VEGF-A is associated 249 
with reduced DC differentiation from hematopoietic progenitors16 and it interferes with TNF-250 
induced NF-kB activation (important for DC functional maturation)17.  251 
HIF-1 targets, VEGF-A and IL-8, aid the recruitment of immature myeloid cells that may stay 252 
undifferentiated (and develop into MDSCs) or develop into TAMs. TAMs have a high level 253 
of plasticity displaying either pro-inflammatory features (M1 phenotype) or 254 
immunosuppressive features (M2 phenotype). Hypoxia-associated molecules (e.g. VEGF-A, 255 
PGE2) stimulate the M2 phenotype18 and the expansion of monocytic (CD11b+) and 256 
granulocytic (Gr1+) MDSCs19. MDSCs are a source of transforming growth factor (TGF)-β, a 257 
crucial immunosuppressive factor, in the TME20. Importantly, these TAMs and Gr1+ myeloid 258 
cells can also render tumors non-responsive to VEGF/VEGFR inhibition (as mentioned later) 259 
and induced angiogenic relapse21.  260 
In addition, the generated mechanical stress (due to high IFP) leads to TGF-β production from 261 
fibroblasts (reviewed in22). TGF-β promotes maintenance of immature DC phenotype which 262 
stimulates differentiation and proliferation of Treg cells and thereby inhibits cytotoxic T cell 263 
(CTL)-mediated responses23. Moreover, TGF-β induces interleukin-receptor associated kinase 264 
(IRAK)-M expression in TAMs, important for an M2 phenotype, that has relevant 265 
implications as the growth rate of transplanted Lewis Lung carcinoma (LLC) cells was 266 
reduced in IRAK-M-/- mice24.  Regarding TANs, TGF-β can induce the protumorigenic N2 267 
phenotype25 although it is not clear to what extent N2 cells exert long-term protumor effects 268 
since neutrophils have a relatively short-life span after they leave the bone marrow and are 269 
particularly sensitive to nutrient deprivation, as typically found in tumors26.  270 
 271 
 272 
Functional activity of T cell populations. Immature DCs may express immunosuppressive 273 
molecules such as IDO and TDO. IDO converts the essential amino acid tryptophan in the 274 
extracellular matrix to kynurenine. Low tryptophan levels starve effector T cells while 275 
favoring Treg expansion. Moreover, MDSCs are a major source of PGE2 that, in absence of a 276 
pro-inflammatory milieu, tends to promote Treg development, induces immunosuppressive 277 
chemokine production and causes an increase in the barrier function of ECs by inhibiting 278 
transendothelial migration of T cells27, 28. In addition, hypoxia-induced expression of 279 
chemokine (C-C motif) ligand-28 (CCL-28) by cancer cells recruits Treg29. The MDSCs that 280 
are attracted and expanded during hypoxic conditions can produce limited amounts of reactive 281 
nitrogen species (e.g. peroxynitrate) that can cause nitration of tyrosines in a T cell receptor 282 
(TCR)-CD8 complex (that impedes interaction with antigen-MHC-complexes30) and some 283 
chemokines like CCL-2. Importantly, nitrated CCL-2 can still serve as a chemoattractant for 284 
monocytes (that can function as MDSCs within a tumor), but not effector T cells31. 285 
Additionally, immune checkpoints can modulate the functional activity of different T cell 286 
populations. In this regard, the HIF-1 pathway is a major inducer of PD-L1/PD-L2 287 
expression32 that inhibits the effector function of T cells (thereby inducing T cell anergy). PD-288 
L1/PD-L2 are commonly expressed by cancer cells, tumor-associated ECs, macrophages, 289 
fibroblasts and DCs33. Moreover, VEGF-A-enhanced expression of PD-1, T cell 290 
immunoglobulin mucin (TIM)-3 and cytotoxic T lymphocyte antigen-4 (CTLA-4) on 291 
intratumoral CD8+ T cells34 increases susceptibility to functional inhibition, thereby 292 
invigorating T cell exhaustion. Furthermore, the acidic nature of the TME also inhibits the 293 
induction of functional CTLs from memory T cells35.   294 
 295 
Collectively, these data highlight that the tumor vasculature is a crucial TME compartment 296 
with the ability to suppress both directly (e.g. through killing of immune cells) and indirectly 297 
(e.g. through preserving the hypoxic TME) antitumor immune responses.  298 
 299 
Tumor-mediated lymphangiogenesis and immunosuppression 300 
 301 
Besides blood vessels, the vascular network includes the lymphatic system. The lymphatic 302 
vessels (LVs) drain interstitial fluid consisting of a plethora of proteins, lipids and cells from a 303 
tissue (for an extensive review see36) to lymph nodes (LNs). The (initial) blunt-ended 304 
capillaries that are embedded in the tissue have an intermittent basement membrane, 305 
discontinuous button-like cell-cell junctions and the lack of pericytes and smooth muscle cells 306 
to facilitate interstitial fluid entry. These capillaries converge into pre-collecting vessels that 307 
traffic lymph to subcapsular sinuses (SCS) in LNs. Lymphatic endothelial cells (LECs) that 308 
line the SCS express CCL-21 and CCL-19 (T cell chemoattractants) and CCL-1 (a DC 309 
chemoattractant). Guided through intranodal sinuses, DCs and T cells enter the T cell zone 310 
(although the majority of T cells also enter directly from the blood via specialized vessels for 311 
lymphocyte trafficking that are found in secondary lymphoid organs such as LNs, called high 312 
endothelial venules or HEVs) that is a predominant site for DC-T cell interactions.  313 
In the TME, cancer cell-derived ligands of VEGF receptor (VEGFR-)3 (VEGF-C, VEGF-D 314 
and VEGF-A) can induce lymphangiogenesis, the equivalent of blood vessel angiogenesis 315 
that leads to the sprouting and attraction of LVs37, 38. Tumor lymphangiogenesis, leads to an 316 
expansion of the intratumoral and peripheral capillaries, collecting lymphatics and draining 317 
lymph nodes (dLNs) and actively contributes to cancer cell dissemination39. Moreover, LECs 318 
function as antigen-presenting cells and induce immunological tolerance and promote the 319 
apoptosis of tumor-reactive CTLs40.  320 
 321 
Here, we discuss some of the most salient features linking tumor-associated lymphatics to the 322 
regulation of antitumor immune responses in the TME, using melanoma as a paradigm of 323 
immunosuppressive and aggressive cancer harnessing the lymphatic system for dissemination 324 
(Fig. 3). 325 
 326 
Lymphatic capillaries in adaptive immune responses.  A lymphatic score (based on 327 
expression of lymphatic markers podoplanin, lymphatic vessel endothelial hyaluronic acid 328 
receptor (LYVE)-1 and VEGF-C) in metastatic cutaneous melanoma patient samples 329 
correlated positively with immune cell (CD45+) infiltration, including immunosuppressive 330 
subtypes (e.g. Treg and inflammatory monocytes) and antitumor subtypes (e.g. CD8+ T 331 
lymphocytes). Consistently, when testing two independent mice models (including a 332 
transgenic K14-VEGFR-3-Ig model) that reduced peritumoral LYVE1 positive dermal 333 
lymphatic capillaries in a B16-F10 melanoma, general immune cell tumor infiltration declined 334 
including the number of Treg, inflammatory monocytes and CD8+ T lymphocytes. Moreover, 335 
this phenotype was associated with decreased DC trafficking from tumor to dLN. This 336 
indicates that whereas lymphatic capillaries are required for T cell infiltration to occur, they 337 
can also cause unproductive adaptive antitumor response41. Moreover, LECs can present self-338 
antigens on MHC-I proteins to promote tolerance that is accentuated by secretion of 339 
immunosuppressive chemokines (TGF-β, IDO, nitric oxide (NO)), high PD-L1/L2 expression 340 
and suboptimal co-stimulatory protein levels (CD80/CD86). Although LECs express basal 341 
levels of PD-L1 thereby modulating peripheral tolerance, PD-L1 expression is increased in 342 
tumor-associated LECs42, likely through HIF-1or interferon (IFN)-γ, which are potent 343 
inducers of PD-L1/L2 expression in LECs. Thus, in case of successful tumoral infiltration by 344 
active CTLs, tumor-associated LECs may attenuate effector T cells' cytolytic activity. 345 
Importantly, LECs increased PD-L1 expression when pulsed with a peptide of the model 346 
antigen ovalbumin (OVA). In the presence of PD-L1 blockade, co-culturing these LECs with 347 
OT-1 CD8+ cells resulted in improved cancer cell killing by OT-1 cells42, thus disclosing a 348 
LEC-mediated mechanism through which immune checkpoint inhibitors (ICIs) might 349 
stimulate CTL activity.  350 
 351 
Low lymphatic flow and high interstitial fluid pressure and immunosuppression. The 352 
lymphatic capillaries drain to larger contractile vessels referred to as collecting lymphatics 353 
that guide lymph towards dLNs. These regulate the lymphatic flow by contractions of 354 
surrounding smooth muscle cells. This is established by a spatiotemporally regulated NO 355 
production by LECs. Tumor-derived VEGF-C attracts LVs into the tumor (although it is 356 
predominant at the peritumoral regions43) and causes an increase in lymphatic pump activity 357 
(including contraction frequency that depended on VEGFR-3 activity which causes tonic 358 
contraction)44. Thus VEGF-C can increase the tissue drainage of cells and TAAs. 359 
Additionally, MDSCs at sites of inflammation are potent NO producers that impair lymphatic 360 
flow45. Although it is not clear to what extent this applies to cancer; yet cancer cells 361 
(especially when hypoxic) secreted cytokines and chemokines that recruit myeloid cells that 362 
can be a source of NO, thereby impairing these contractile cycles and the drainage of 363 
TAAs/TAA-presenting DCs to dLNs. Moreover, reduced lymph drainage and the lack of 364 
(functional) intratumoral LVs contributes to the high IFP43 and subsequent 365 
immunosuppressive effects. Improving the lymph vessel function as well as reducing the 366 
intratumoral MDSCs are seemingly important targets in improving antitumor immunity.  367 
 368 
The lymph node microenvironment and antitumor immunity. In essence, the LN is a tissue 369 
for the recognition and presentation of antigens to prime or tolerogenize adaptive immune 370 
responses. A tumor drains various secreted factors that influence the LN microenvironment in 371 
favor of immunosuppression. This counteracts antitumor immunity and generates a hospitable 372 
environment for the seeding and growth of cancer cells (‘lymphovascular premetastatic 373 
niche’). In line with this, B16-F10 cells injected into the LN, but not subcutaneously, are 374 
rejected in a CD8+ cell dependent manner46. Moreover, micrometastasis-free dLNs from 375 
melanoma patients have increased levels of certain immunostimulating cytokines as compared 376 
to non-sentinel LNs and micrometastases positive LNs. These include IFN-γ (suggesting 377 
TAAs-specific immunity), IL-2 (B and T cell proliferation stimulus) and granulocyte 378 
macrophage colony-stimulating factor (GM-CSF; DC maturation factor)47. Thus, initially, an 379 
immune response is incited in a dLN that can also be sufficient to prevent colonization. Yet, 380 
the tumor eventually overcomes this protective effect. In agreement with this, in the presence 381 
of a subcutaneous B16-F10 tumor, intralymphatic B16-F10 injection resulted in effective 382 
tumor growth46. This can be a result of tumor-derived secreted factors and immature DCs, 383 
and, recruitment of MDSCs. Regarding the former study using an OVA-expressing B16-F10 384 
melanoma model, additional VEGF-C overexpression led to reduced IFN-γ-producing CD8a+ 385 
OT-1 cells in the dLN, possibly due to enhanced lymph flow and LEC-mediated tolerogenic 386 
events48. Moreover, in a different melanoma model (B16-F1), CCL-21 expression in dLNs 387 
reduced progressively in time after tumor injection, as compared to unchallenged LNs49. This 388 
could possibly result in an impaired T cell retention, which enables clonal expansion before 389 
LN egress50.  390 
Thus the lymphatic system, can support (draining of TAAs/TAA-presenting DCs) as well as 391 
attenuate (tolerogenic events) antitumor immune responses.  392 
 393 
  394 
Vascular targeting approaches: limitations and opportunities for immunotherapy 395 
 396 
The discussion so far establishes that the tumor vasculature (both ECs and LECs) is an 397 
essential regulator of the intersection between cancer cells and immune compartment within 398 
the TME. By extension, tumor vasculature can henceforth play an important role in regulating 399 
responses to cancer immunotherapy28. Briefly, immunotherapy aims to modulate the host’s 400 
immune system to promote antitumor immunity and it broadly includes treatments with 401 
cytokines/immunomodulatory drugs (IMDs), monoclonal antibodies (mAbs), adoptive cell 402 
transfer and anticancer vaccines, such as DC vaccines51, 52, 53. However, the current landscape 403 
of cancer immunotherapy is largely dictated by ICIs, principally because of their clinical 404 
success and prominent and durable responses in patients of several histological tumor types54, 405 
55, 56. The most prominent ICIs are mAbs blocking the activity of CTLA-4, PD-1 and PD-L1. 406 
Emerging evidence, moreover, highlights that the type of cancer cell death, may favor or 407 
impede antitumor immunity and regulate the success of ICIs in combinatorial regimens.57 408 
Indeed, antitumor immunity can be accentuated via the induction of immunogenic cell death 409 
(ICD) in cancer cells, thus acting as 'in situ' vaccines58, 59. Major hallmarks of ICD are the ER 410 
stress-regulated and spatiotemporally-defined emission of danger signals (most prominently, 411 
surface calreticulin, secreted ATP, and passively released high mobility group box (HMGB)-412 
1, nucleic acids, dsRNA, dsDNA)60, 61. Moreover, ICD is uniquely associated with 'altered-413 
self mimicry' elicited by type I IFN cytokines (consisting of IFN-α and IFN-β) and a pathogen 414 
response-like chemokine (PARC) signature (consisting of C-X-C ligand (CXCL)-1, CCL-2, 415 
CXCL-10 or homologs thereof)62, 63. Of note, cancer cells succumbing to ICD can also be 416 
used for creating next-generation DC-based vaccines64. 417 
Although immunotherapy has prolonged survival of many cancer patients (as evidenced by a 418 
string of FDA-approvals in a relatively short-span of time), there are still various hurdles 419 
limiting its therapeutic efficacy.65, 66 These are in large part caused by the profoundly 420 
immunosuppressive TME and cancer cell-autonomous mechanisms of immunoevasion (e.g. 421 
loss of TAAs or MHC expression levels, dysregulation of IFN signaling, dysregulation of 422 
danger signaling, immunogenic phagocytosis) (reviewed in 66, 67). As discussed above, the 423 
aberrant tumor vasculature can counteract immunotherapy due to ill-delivery of the mAbs (as 424 
a result of the immature and badly-structured blood vasculature) and restrain anticancer 425 
immune responses by favoring presence of immunosuppressive immune cells (e.g. presence 426 
of MDSCs, M2 TAMs and Treg cells (Fig. 4) over immunostimulatory immune cells (mainly 427 
CD8+ T cells).  Compelling evidence indicate that spatial, functional orientation and density 428 
of T lymphocytes within the tumor is associated with good patient prognosis across many 429 
cancer types64, 68, 69.  430 
Based on these emerging lines of evidences, we surmise that targeting of tumor vasculature 431 
might improve the efficacy of cancer immunotherapy. In fact, this is one of the main reasons 432 
behind recent proposals to target the tumor vasculature in combination with cancer 433 
immunotherapy. In the next section, we describe and discuss some potential combinatorial 434 
strategies using antiangiogenic and immunotherapy approaches. 435 
  436 
 437 
Antiangiogenic treatment, vessel normalization and immunotherapy. Targeting of the 438 
VEGF/VEGFR axis has been the most preferred combinatorial approach for immunotherapy-439 
related studies. Initially, monotherapy with antiangiogenic agents, such as the anti-VEGF 440 
antibody bevacizumab, by blocking the VEGF/VEGFR dependent survival and growth of the 441 
blood vasculature, was thought to starve the tumor thus halting tumor progression and 442 
improving patient survival. In spite of promising initial preclinical results, this vessel-443 
targeting therapy, called vessel blocking, did not elicit the expected results in cancer patients 444 
and failed to show substantial improvements in response rates or survival benefits70. Later on, 445 
preclinical studies showed that vessel pruning leads to an increase hypoxic (but not ischemic) 446 
tumor areas71, which in turn supported tumor growth and metastatic dissemination. Indeed, 447 
hypoxia induced by anti-VEGF/VEGFR therapy may be in part responsible for the angiogenic 448 
relapse and therapy resistance observed after vessel blocking strategies, which may involve 449 
distinct immunosuppressive immune-cell populations, including Gr1+CD11b+ and TAMs72. A 450 
recent study showed that these myeloid cells are recruited by the cancer cell-derived, 451 
angiostatic chemokine, CXCL14, which instigated PI3K signalling in these myeloid cells.  In 452 
line, inhibition of this pathway was required for the durable effects of antiangiogenic 453 
therapy21.  454 
 455 
However, in experimental mouse models, Bevacizumab (Avastin®, a recombinant humanized 456 
antibody that binds VEGF isoforms) treatment resulted in a transient remodeling of the tumor 457 
vasculature by increasing the number of matured (i.a. pericyte covered) vessels, decrease 458 
permeability, reduce IFP and increase perfusion in neuroblastoma xenografts. This vessel 459 
‘normalizing’ effect was transient as the observed intratumoral penetration of topotecan and 460 
etoposide only improved the first days after Bevacuzimab treatment73. Another study showed 461 
that DC-101 (mouse VEGFR-2 specific monoclonal antibody) treatment of glioma xenografts 462 
increased vessel normalization that is associated with a time window for the synergistic effect 463 
of the combined treatment with radiotherapy, an inducer of ICD71.  464 
Hence, these data suggest a window of opportunity to establish a synergistic effect between 465 
tumor vessel normalizing agents and immunotherapy74.   466 
They also suggest that ‘normalizing’ or ‘healing’, rather than destroying, the erratic tumor 467 
vasculature may restore normal structural functional aspects of the vessels, which elicit a 468 
better therapeutic outcome. In line with this, ‘vessel normalization’ by improving vessel 469 
functionality, results in better perfusion of the tumors, and by increasing the transporting 470 
capability of vessels, improves both drug delivery (of small chemotherapeutics as well as 471 
mAbs) and therapy responses, which strongly depend on adequate tumor blood supply75, 76. 472 
Moreover, the resulting improvement in tumor oxygenation may increase the efficacy of 473 
immunotherapy. Indeed, as mentioned above, hypoxia and poor intratumoral infiltration of T 474 
cells, caused by the poor perfusion of the aberrant tumor vessels, attenuate the efficacy of ICI-475 
based immunotherapy32, 77. Opposite to this, hyper-oxygenation increases CTL activity, and 476 
correlates with improved clinical responses to ICIs78.  477 
In the context of immunotherapy, DC-101 treatment also associated with an increased B16-478 
F10 melanoma infiltration of adoptively transferred T cells and an enhanced tumor growth 479 
delay79. In addition, DC-101 treatment led to tumor vessel normalization and reduced tumor 480 
hypoxia only in low (10-20 mg/kg) but not high dose (40 mg/kg) treatments. Moreover, this 481 
was accompanied with important changes in the TME with a shift towards tumorsuppressing 482 
Th1-mediated immune responses, including TAM polarization to an M1-like phenotype and 483 
increased CD4+ and CD8+ T cell tumor infiltration. These changes in the TME also enhanced 484 
the effect of vaccine-based immunotherapy80. In addition, transient targeting of 485 
VEGF/VEGFR axis may reverse DC maturation defects81 and lower VEGF-A induced PD-1, 486 
TIM3 and CTLA-4 expression on CD8+ T cells34; however, Bevacizumab may also inhibit the 487 
phagocytic ability of DCs and macrophages82.  488 
Besides blocking the VEGF/VEGFR axis, other strategies have been shown to induce vessel 489 
normalization83, 84. Recently, the antimalarial compound, and first generation autophagy 490 
inhibitor chloroquine (CQ), was found to elicit in vivo vessel normalization through the 491 
activation of the Notch-signalling pathway in blood endothelial cells85 leading to a more 492 
quiescent EC phenotype86. Both the tumor vasculature normalizing and antimetastatic effects 493 
of CQ were completely blunted when melanoma cells were implanted in mice lacking Notch1 494 
in ECs. By normalizing the abnormal tumor vasculature CQ attenuated tumor hypoxia and 495 
caused the generation of a more EC solid barrier that impeded cancer cells’ intravasation and 496 
metastasis86. Intriguingly, a recent preclinical study showed that, in spite of its mild 497 
immunosuppressant effects, CQ does not impair antitumor immunity in vivo, and can 498 
synergize with immunotherapy87, 88. Another therapeutic strategy may entail reprogramming 499 
the ECs glycolytic phenotype. Recent studies revealed that ECs depend predominantly on 500 
glycolysis for ATP production. Furthermore, this glycolytic phenotype is aggravated in the 501 
TME by the enhanced VEGF signalling and contributes to vascular dysfunction89, 90.  502 
A recent study showed that blockade of the key glycolytic activator 6-Phosphofructo-2-503 
kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) normalized blood vessels, an effect that was 504 
associated with a tightened vascular barrier (fewer metastases) and increased perfusion 505 
(improved chemotherapy efficacy)91. Thus, pharmacological inhibitors targeting endothelial 506 
cell glycolytic metabolism, could reverse tumor-induced alterations in ECs leading to a vessel 507 
normalization phenotype92. A therapeutic strategy warranting further experimental and 508 
clinical confirmation validation. 509 
Moreover, recent insights show the relevance of non-protein coding micro-RNAs (miRNAs) 510 
in angiogenesis (see 93, 94 for a more detailed overview) by regulating gene expression via 511 
RNA interference. For example, pro-angiogenic miRNAs can be induced by hypoxia 512 
(including miR-210 and miR-494)95 or, oppositely, certain miRNAs affect the VEGF/VEGFR 513 
pathway (e.g. miR-16 (that also interferes with TGF-β signalling))96 to modulate 514 
angiogenesis. Interestingly, cancer cell-secreted vesicles containing miR-494 can promote 515 
angiogenesis in ECs97. Thus, as tumor-associated conditions can promote the expression of 516 
miRNAs to support the highly angiogenic TME (either cell autonomously or via cross-517 
communication), miRNAs could be considered as potential targets of antiangiogenic/vessel 518 
normalizing approaches. Nevertheless, this is still an emerging field that requires further 519 
research to reach a better understanding of how (specific) targeting miRNAs may enhance 520 
immunotherapy efficacy. 521 
Aside from VEGF-A, other proteins that promote immunosuppression and angiogenesis may 522 
be interesting targets. IDO can stimulate angiogenic events (effect of kynurenine on ECs98) 523 
besides establishing immunosuppressive events (tryptophan depletion). Interestingly, in the 524 
context of immunotherapy, IDO inhibition synergizes with ICI approaches in preclinical 525 
models99 which may therefore be contributed through IDO-mediated effects on tumor 526 
vasculature. Furthermore, secretion of galectin-3 (whose expression is induced by hypoxia 527 
and nutrient deprivation) inhibits the effector function of CD8+ T cells100 and also invigorates 528 
VEGF and bFGF-induced angiogenic events in ECs101. Therefore, targeting these crosstalks 529 
and signalling axis could shape a TME in favour of antitumor immunity; however, these 530 
possibilities need further investigations and validation in preclinical models. 531 
Interestingly, although vessel normalization can result in improved lymphocyte infiltration 532 
and a less therapy-resistant TME, the infiltration of CD4+ T cells can induce vessel 533 
normalization as well. In a recent and elegant study, adoptive CD4+ T cell transfer was 534 
associated with reduced hypoxia and leakiness, and, increased perfusion, while CD4 depletion 535 
reduced vessel pericyte coverage102. Together this suggests a reciprocal feedback loop in 536 
which a lymphocyte-admissible TME by vessel normalization has subsequent positive effects 537 
on the vasculature integrity.  538 
 539 
Despite only few studies focusing on targeting the tumor-associated lymphatic structures, its 540 
relevance for immunotherapy outcome should not be underestimated. A study utilizing a B16-541 
F10-OVA model showed that VEGF-C overexpression was able to protect against the 542 
antitumor immune response elicited by OVA-vaccination48. In a transgenic model removing 543 
dermal lymphatic capillaries, the efficacy of a vaccination approach was impaired (due to 544 
impaired development of antigen-specific CD8+ cells), whereas an ACT approach (OT-1 cells 545 
activated with OVA-peptide-loaded DCs) was more effective (possibly due to reduced 546 
immunosuppressive TME)41. 547 
 548 
Taken together, the aforementioned studies suggest that targeting angiogenesis, with vessel 549 
normalizing strategies in particular, can improve the efficacy of immunotherapies.  550 
 551 
Specific tumor vasculature targeting strategies to improve outcome of anticancer therapy. 552 
Administration of antitumor immunity stimulating cytokines such as IL-2, TNF-α and IFN-γ 553 
can be beneficial; however, it is limited by maximum tolerated doses in patients103. New 554 
approaches have been developed to restrict the dose required for a beneficial therapeutic 555 
effect on the tumor. Treatment of colorectal cancer bearing mice with TNF-α or IFN-γ 556 
conjugated to the tumor vascular homing peptide TCP-1 resulted in tumor growth delay, 557 
increased TUNEL staining in the tumor and reduced systemic toxicity compared to 558 
unconjugated cytokines. Importantly, the TME also improved as the CD8+ (TCP-1/TNF-α) 559 
and CD4+ (TCP-1/TNF-α, TCP-1/IFN-γ) infiltration increased104 and the vasculature 560 
normalized (TCP-1/TNF-α)105. TCP-1/TNF-α improved 5-FU delivery and, due to the 561 
synergistic effects, improved drug-induced tumor control105. In addition, conjugating TNF-α 562 
to a Cys-Asn-Gly-Arg-Cys (NGR) peptide (recognizing an aminopeptidase N (CD13) isoform 563 
on tumor-associated ECs) led to increased adhesion molecule expression on ECs, increased 564 
CD8+ T cell infiltration in B16-OVA melanoma and improved outcome of both ACT (with 565 
OVA-specific in vitro-activated OT-1 cells) and DC-OVA vaccine approaches106. Other 566 
approaches use a small immune protein (L19) to target the additional extra-domain (ED-B) of 567 
fibronectin associated with tumor neovasculature. Combined with either dacarbazine107 or 568 
radiotherapy108, 109, L19-IL2 treatment enhanced the efficacy of the therapy modality which 569 
was suggested to be CD8+ T cell dependent108 possibly due to the ICD-inducing ability of 570 




To maintain a cancer cell permissive and immunosuppressive microenvironment enabling 575 
tumor growth and dissemination, cancer cells educate and corrupt stromal cells. Emerging 576 
evidence indicate that cancer cell-induced effects on both the blood and lymph endothelium 577 
are crucially involved in the generation and maintenance of an immunosuppressive TME. In 578 
particular, the tumor vasculature can actively suppress antitumor immune responses by 579 
providing a barrier to T cells infiltration in the tumor, by selectively killing T cells or by 580 
increasing tolerogenicity against tumor-associated antigens. Given that spatial, functional 581 
orientation and density of T lymphocytes within the tumor (i.e. the immunoscore110) is one of 582 
the main predictor of therapy responses in patients, this has generated the therapeutic 583 
perspective of targeting the abnormal tumor vasculature to relieve critical TME-associated 584 
conditions that antagonize the efficacy of immunotherapy. In line with this, an increasing 585 
amount of preclinical data indicates that vessel normalization strategies, eliciting a transient 586 
improvement of the aberrant structural and functional features of the tumor blood vessels, 587 
results in lowering tumor hypoxia and increasing drug delivery, thereby enabling immune cell 588 
infiltration and synergize with immunotherapies for more durable effects111. These findings 589 
have important implications for the design of a combinatorial strategy using vessel 590 
normalizing agents with immunotherapy. However, there are many outstanding questions and 591 
challenges that remain to be addressed. 592 
First, alternative strategies to VEGFR-blockade aiming to sustain the effects of antiangiogenic 593 
therapies, are required. To this end, emerging ECs metabolic signatures and EC trafficking 594 
pathways, may offer more efficient alternative targets and the availability of pharmacological 595 
inhibitors of these pathways (e.g. choloroquine) should favor their future applications.  Also, 596 
the role of other stromal cells, like cancer-associated fibroblast should be considered as these 597 
can promote angiogenesis as well. Given the emerging relevance of the dynamic intersection 598 
between the immune cells (i.e. T cells, myeloid cells, DCs) and ECs, in angiogenesis and 599 
relapse after antiangiogenic therapy, more studies are needed to reveal potential targets that 600 
blunt the recruitment of immunosuppressive immune cells fostering tumor regrowth.  Further, 601 
when applying tumor vasculature targeting regimens, the effects of additional modulation of 602 
the lymphatics (by e.g. VEGFR-3 inhibition) should be carefully considered, since whether 603 
modulation of lymphangiogenesis overcomes tolerogenic events or impairs stimulation of an 604 
adaptive response, remains still ill-defined. Moreover, whether the concept of vessel 605 
normalization can be extended to lymphatic vessels is still elusive.  606 
In conclusion, targeting the tumor vasculature to induce vessel normalization may provide a 607 
promising strategy to optimize the efficacy of currently employed immunotherapies as it 608 
could lower the level of immunosuppression in the TME. Yet, it is clear that if we want to 609 
exploit the full potential of the immune system to cure cancer, we will have to act at multiple 610 
levels in order to ‘normalize’ the TME. 611 
 612 
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  1066 
Figure 1. Tumor-associated blood vasculature is a major influencer of the tumor 1067 
microenvironment (TME). (Upper left panel) A well-organized vessel network ensures full-1068 
covering of nutrient supply. (Lower left panel) These vessels are matured with an endothelial 1069 
cell layer surrounded by a basement membrane and pericytes (like smooth muscle cells). The 1070 
endothelial layer is characterized by tight intercellular junctions. Oppositely, due to high pro-1071 
angiogenic signaling, the network of tumor-associated blood vessels (upper right panel) is 1072 
chaotic, low in pericyte coverage and has loose inter-endothelial cell junctions (lower right 1073 
panel). This generates leaky vessels that increases interstitial fluid (IFP) pressure. Common 1074 
blunt-ended or collapsed vessels results in tumor regions that are starved from nutrients 1075 
including oxygen (hypoxic cells indicated in green). Moreover, the glycolytic nature of the 1076 
(hypoxic) tumor cell acidifies the pH in the TME.  1077 
 1078 
Figure 2. The nature of the TME influences immune cell composition and hampers 1079 
antitumor immunity. Firstly, hypoxia is a common feature of the TME caused by the 1080 
abnormal vascular structure and function. Dysregulated adhesion [1] and differential 1081 
admittance among immune cell types is caused by several hypoxia-related factors in the TME, 1082 
including VEGF-A, PGE2 and IL-10. Together these induce FasL expression on ECs that 1083 
affects survival of effector T cells (rather than Tregs) [2]. In addition, expression of CLEVER-1084 
1/stabilin-1 on tumor-ECs and hypoxia-related chemokine CCL-28 in the TME further aid the 1085 
recruitment of, preferentially, Tregs[3]. The hypoxic TME recruits monocytes that give rise to 1086 
MDSC, TAM and TAN populations [4] in the tumor and induces a differential and functional 1087 
immature phenotype of DCs [5]. This  collectively support an immunosuppressive TME. 1088 
Immature DCs produce IDO to favor Treg differentiation from naïve T cells and inhibit CTL 1089 
function [6]. MDSCs are a source of reactive nitrogen species that nitrate CCL-2 and 1090 
tyrosines of the T cell receptor that recruits more monocytes [7] and impedes CTL antigen 1091 
recognition [8], respectively. Moreover, VEGF-A induces the expression of PD-L1, TIM-3 1092 
and CTLA-4 on CTLs to render them more susceptible to functional inhibition [9]. Secondly, 1093 
as a result of a more glycolytic metabolism the TME acidifies (low pH), thereby inhibiting the 1094 
induction of antigen specific CTLs [10]. Thirdly, the leaky tumor vessels induce a high 1095 
interstitial fluid pressure (IFP) that leads to high TGF-β production that is also implicated in 1096 
TAM M2 polarization, maintaining immature DC phenotype and differentiation and 1097 
proliferation of Tregs [11].  1098 
 1099 
Figure 3. The effects of tumor-associated lymphatic endothelium on antitumor 1100 
immunity. The lymphatic vessels (green) guide antigens and DCs to lymph nodes to facilitate 1101 
the DC-T cell interaction to prime T cells (only if the LN microenvironment allows this to be 1102 
productive). Notably, lymphatic vessels are more common peritumorally, while intratumoral 1103 
vessels are prone to collapse. Moreover, defects in contractile events for lymph flow impair 1104 
drainage. Thus, tumor drainage, albeit physically hampered in a tumor, is required for 1105 
developing antitumor immunity. Importantly, additional LEC features (intrinsic or tumor-1106 
induced) counteract the induction of an adaptive immune response. This is exemplified by the 1107 
increased PD-L1 expression and protolerogenic cell surface protein composition (co-1108 
inhibitory over co-stimulatory factors). Drainage of immunosuppressive immune cell types 1109 
(e.g. MDSCs, immature DCs) influence the LN microenvironment to favor 1110 
immunosuppressive populations (e.g. Treg and MDSCs) that facilitate lymphovascular 1111 
premetastatic niche formation. Moreover, reduced CCL-21 levels in dLNs diminish the 1112 
opportunity for DCs and naïve T cells to interact and impairs T cell retention for efficient 1113 
expansion before LN egress. 1114 
 1115 
Figure 4. Hurdles established by the tumor vasculature that limit immunotherapy 1116 
efficacy. As discussed above, the TME often thwart CTL presence in the TME due to 1117 
inducing apoptosis/ill-adhesion or by functional inhibition even when infiltrated. This low 1118 
number of TAA-specific CTLs affects the harvest from tumor biopsies for adoptive T cell 1119 
transfer-based immunotherapy. Moreover, delivery of administered regimens including 1120 
monoclonal antibodies, DCs and T cells can be hindered due to ill-perfusion. Yet, the TME 1121 
can still functionally inhibit the transferred DCs when infiltrated. 1122 
 1123 




